pharmaceutical investing Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
pharmaceutical investing Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Forge Resources Intersects 3.4 g/t Gold over 44.75 Metres, and 800 Metre Step-Out Discovers 1.04 g/t Gold over 55.52 Metres at Alotta, Yukon
